Page 4 - Charlesj Fisher Jr News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Charlesj fisher jr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Charlesj Fisher Jr Today - Breaking & Trending Today

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

/PRNewswire/ Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today. ....

Susan Noonan , Tony Russo , Aethlon Hemopurifier , Jim Frakes , Charlesj Fisher Jr , Company Contact , Drug Administration , Sa Noonan Communications , Russo Partners , Company Annual Report On Form , Exchange Commission , Prnewswire Aethlon Medical Inc , Aethlon Medical Inc , Securities Exchange , Continuous Renal Replacement Therapy , Aethlon Medical , Early Feasibility Study , Breakthrough Device , Investigational Device Exemption , Pittsburgh Medical Center Hillman Cancer , Emergency Use Authorization , Securities Act , Securities Exchange Act , Early Feasibility Studies , Emergency Use , Annual Report ,

Aethlon Medical Publishes Case Studies of Two Critically Ill COVID-19 Patients Treated with the Hemopurifier®

/PRNewswire/ Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced the. ....

Susan Noonan , Tony Russo , Aethlon Hemopurifier , Jim Frakes , Charlesj Fisher Jr , Company Contact , Sa Noonan Communications , Russo Partners , Company Annual Report On Form , Exchange Commission , Exosome Sciences Inc , Research Square , Aethlon Medical Inc , Securities Exchange , Aethlon Medical , Whole Virus , Lectin Affinity Cartridge , Critically Ill Patients , Continuous Renal Replacement Therapy , Early Feasibility Study , Investigational Device Exemption , Pittsburgh Medical Center Hillman Cancer , Breakthrough Device , Exosome Sciences , Securities Act , Securities Exchange Act ,

Zacks Small Cap Research - AEMD: Establishing The Infrastructure To Support Expanding Opportunities

AEMD: Establishing The Infrastructure To Support Expanding Opportunities
01/29/2021
Management team with vast healthcare experience
Aethlon Medical Inc. (NASDAQ:AEMD), a medical technology company engaged in developing products to diagnose and treat diseases in oncology and viral diseases that are life and organ threatening and not addressed with already approved treatments, is setting up internal infrastructure to support its growing opportunities. Earlier this month, AEMD expanded its executive team in order to support its growth prospects. AEMD made two key appointments. Guy Cipriani was named SVP and Chief Business Officer. He will be responsible for business development and partnerships and involved in fundraising and corporate development. Steven LaRosa, M.D., has become AEMD’s Chief Medical Officer, with responsibility for the clinical development of the Hemopurifier®. Both have significant industry experience. The company’s CEO Charles J. Fisher, Jr., M.D ....

Steven Larosa , Aethlon Hemopurifier , Charlesj Fisher Jr , National Institute For , University Of Pittsburgh , Aethlon Medical Inc , Craniofacial Research , Hillman Cancer Center , Chief Business , Medical Officer , National Institute , Cancer Center , ஸ்டீவன் லரோசா , தேசிய நிறுவனம் க்கு , பல்கலைக்கழகம் ஆஃப் பிட்ஸ்பர்க் , கிரனிோபசியல் ஆராய்ச்சி , ஹில்மேன் புற்றுநோய் மையம் , தலைமை வணிக , மருத்துவ அதிகாரி , தேசிய நிறுவனம் , புற்றுநோய் மையம் ,

Aethlon Medical Announces First Patient Treated in First-in-Human Clinical Trial of HEMOPURIFIER® in Head and Neck Cancer

Share this article
Share this article
SAN DIEGO, Dec. 16, 2020 /PRNewswire/ Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs in viral diseases, oncology and inflammation, announced today that the first patient has been treated in the Company s first-in-human Early Feasibility Study (EFS) evaluating the HEMOPURIFIER® in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. The study is enrolling patients at UPMC Hillman Cancer Center in Pittsburgh, PA. (
The EFS, which is the device equivalent of a Phase 1 clinical trial for a drug or biologic, is a single center, open label trial in 10 to 12 subjects. The study is evaluating the HEMOPURIFIER® for reducing cancer-associated exosomes prior to the administration of standard-of-care pembrolizumab (KEYTRUDA®), which is a first-line therapy for patients with recurrent and/or metastatic squamous cell carcinoma of the hea ....

Susan Noonan , Tony Russo , Dan Zandberg , Aethlon Hemopurifier , Jim Frakes , Charlesj Fisher Jr , Company Contact , University Of Pittsburgh School Medicine , Sa Noonan Communications , Russo Partners , Exchange Commission , Company Annual Report On Form , Exosome Sciences Inc , University Of Pittsburgh , Aethlon Medical Inc , Securities Exchange , Hillman Cancer Center , Aethlon Medical , Early Feasibility Study , Cancer Center , Medical Oncologist , Associate Professor , Pittsburgh School , Principal Investigator , Chief Executive Officer , Breakthrough Device ,